Pure Global AI
NCT06322992Not yet recruiting

App-Assisted Day Reconstruction to Reduce Treatment Burden and Logistic Toxicity in Cancer Patients - Aim 3

Daynamica, Inc.ClinicalTrials.gov
Verified
Study focus
Disease/Condition
Cancer
Study type
Observational
Sponsor & location
Primary sponsor
Daynamica, Inc.
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
May 01, 2025
Enrollment
60 participants
Primary outcome

APP satisfaction,APP rating

Summary

The goal of this observational study is to develop a mobile app for cancer patients
 undergoing treatments. In Aim 3, patients will rate the quality of the app using the Mobile
 App Rating Scale (MARS) and their satisfaction with the three key app features. The outcome
 of this project will be a final prototype app with 70% of patients indicating an overall MARS
 score of 4.0 or more and satisfaction with the three features.

ICD-10 classifications
Carcinoid syndromeOther chemotherapyCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Prepuce
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06322992
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06322992 through Pure Global AI's free database. This phase not specified trial is sponsored by Daynamica, Inc. and is currently Not yet recruiting. The study focuses on Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.